Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 143 No. 0102 (2013)

Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland

  • Mark Pletscher
  • Rafael Plessow
  • Klaus Eichler
  • Simon Wieser
Cite this as:
Swiss Med Wkly. 2013;143:w13732


OBJECTIVES: Atrial fibrillation is a major risk factor for ischemic stroke and anticoagulation therapy is indicated to reduce risk. Dabigatran is a new oral anticoagulant that does not require INR monitoring. This study evaluated the cost-effectiveness of dabigatran versus vitamin K antagonists for stroke prevention in atrial fibrillation in Switzerland.

METHODS: A Markov model simulating the course of treatment and occurrence of clinical events in two treatment arms over the lifetime of patients was adapted to the Swiss context. The adaptation included the cost of anticoagulation therapy and clinical events in Switzerland. The cost of inpatient care was estimated on data of all inpatient hospital stays in 2008. The calculation of outpatient care costs was based on peer reviewed studies, expert interviews and local tariffs.

RESULTS: Patients treated with dabigatran had a higher life expectancy and experienced more quality adjusted life years (QALY) while incurring higher costs than patients treated with vitamin K antagonists. The estimated incremental cost-effectiveness ratio (ICER) was CHF 25,108.‒ per QALY with 110 mg and CHF 9,702 per QALY with 150 mg of dabigatran. A sequential dosage scheme, in which 150 mg are administered up to the age of 80 years and 110 mg thereafter, resulted in an ICER of CHF 10,215 per QALY. A sensitivity analysis confirmed that these results are robust.

CONCLUSIONS: Dabigatran can be considered cost-effective in comparison with vitamin K antagonists in the Swiss context. The higher drug cost of dabigatran is compensated by savings in INR monitoring, lower cost of clinical events and QALY-gains.

Key words:dabigatran; warfarin; marcoumar; oral anticoagulation; atrial fibrillation; stroke prevention; vitamin K antagonist; VKA; cost; cost-effectiveness; QALY; ICER; Switzerland


  1. Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM. Cost-effectiveness of warfarin: trial versus “real-world” stroke prevention in atrial fibrillation. Am Heart J. 2009;157(6):1064–73.
  2. Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective. Thromb Haemostasis. 2011;105(5):908–19.
  3. Conen D, Osswald S, Albert CM. Epidemiology of atrial fibrillation. Swiss Med Wkly. 2009;139(25–26):346–52.
  4. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention. The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285(18):2370–5.
  5. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349(11):1019–26.
  6. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation. The Framingham study. Stroke. 1996;27(10):1760–4.
  7. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation. Eur Heart J. 2010;31:2369–429.
  8. Stangier J. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Pharmacokinet. 2008;47(5):285–95.
  9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.
  10. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly Identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875–6.
  11. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation / clinical perspective. Circulation. 2011;123(22):2562–70.
  12. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2010;154(1):1–11.
  13. Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: Quantitative benefit-harm and economic analyses. BMJ. 2011;343.
  14. Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart. 2012;98(7):573–8.
  15. Fattinger K, Frisullo R, Masche U, Braunschweig S, Meier P, Roos M. No clinically relevant drug interaction between paracetamol and phenprocoumon based on a pharmacoepidemiological cohort study in medical inpatients. Eur J Clin Pharmacol. 2002;57(12):863–7.
  16. Marko P, Flückiger H. Orale Antikoagulation mit Warfarin. Pharma-Kritik. 1993;15(8):29–32.
  17. Kristiansen C, Lassen JF, Dahler-Eriksen BS, Dahler-Eriksen K, Larsen TB, Brandslund I. Evaluation of a simple dosage scheme for transition from phenprocoumon to warfarin in oral anticoagulation. Thromb Res. 2000;98(2):157–63.
  18. van Leeuwen Y, Rosendaal FR, van der Meer FJM. The relationship between maintenance dosages of three vitamin k antagonists: Acenocoumarol, warfarin and phenprocoumon. Thromb Res. 2008;123(2):225–30.
  19. European Medicines Agency – Committee for Medicinal Products for Human Use (CHMP). Product information as approved by the CHMP on 24 May 2012, pending endorsement by the European Commission. Annex I: Summary of Product Characteristics 2012.
  20. Swiss National Bank. Monthly Statistical Bulletin. 2011;86(2).
  21. Roskell NS, Lip GYH, Noack H, Clemens A, Plump JM. Treatments for stroke prevention in atrial fibrillation: A network meta-analyses and indirect comparisons versus dabigatran etexilate. Thromb Haemost. 2010;104(6):1106–15.
  22. Walker AM, Bennett D. Epidemiology and outcomes in patients with atrial fibrillation in the United States. Heart Rhythm. 2008;5(10):1365–72.
  23. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. Br Med J. 2000;320(7244):1236–9.
  24. Fritschi J, Raddaz-Müller P, Pirmin S, Wuillemin WA. Patient self-management of long term oral anticoagulation in Switzerland. Swiss Med Wkly. 2007;137:252–8.
  25. Lauper P. Antikoagulanzien. Unpublished online survey commissioned by Boehringer Ingelheim GmbH. Hergiswil: GfK Switzerland AG, GfK HealthCare; 2010.
  26. Niederer A, Wuillemin WA, de Moerloose P. Orale Antikoagulation: Praktisches Vorgehen. Swiss Med Forum. 2001;1(17):425–30.
  27. Swiss Compendium of Medicines. Basel: Documed AG; 2011 [updated 2011 September; cited 2011 September 30]. Available from:
  28. Monthly index of medical specialities. Bern: Swiss Federal Office of Public Health; 2011 [updated 2011 September; cited 2011 September 30]. Available from:
  29. List of laboratory analyses. Bern: Swiss Federal Office of Public Health; 2011 [updated 2011 July 1; cited 2011 September 30]. Available from:
  30. TARMED Suisse tariff browser. Bern: TARMED Suisse; 2011 [updated 2010 April 1; cited 2011 September 30]. Available from:
  31. Monthly index of medical specialities. Bern: Swiss Federal Office of Public Health; 2012 [updated 2011 September; cited 2012 September 26]. Available from:
  32. Swiss Federal Statistical Office. Medical statistics of hospitals 2008. Neuchâtel: Swiss Federal Statistical Office; 2010.
  33. Swiss Federal Statistical Office. Statistics of diagnosis related cost: cost per case by AP-DRG and hospital typology – year 2008. Neuchchâtel: Swiss Federal Statistical Office; 2010.
  34. Swiss Federal Statistical Office. Costs and financing of the health care system – detailed results 2008 and recent developments. Neuchâtel: Swiss Federal Statistics Office; 2011.
  35. Wieser S, Rüthemann I, De Boni S, Eichler K, Pletscher M, Radovanovic D, et al. Cost of acute coronary syndrome in Switzerland in 2008. Swiss Med Wkly. 2012;142:0.
  36. santésuisse. Inpatient tariffs in hospitals. March 2008 ed. Solothurn: tarifsuisse AG; 2008.
  37. Swiss Federal Statistical Office. Statistics of social medical insitutions 2008 – statistical table. Neuchâtel: Swiss Federal Statistical Office; 2010.
  38. Brüggenjürgen B, Rupprecht HJ, Willich SN, Spannagl M, Ehlken B, Smala A, et al. Cost of atherothrombotic diseases – myocardial infarction, ischaemic stroke and peripheral arterial occlusive disease in Germany. J Public Health. 2005;13(4):216–24.
  39. Mahler MP, Zuger K, Kaspar K, Haefeli A, Jenni W, Leniger T, et al. A cost analysis of the first year after stroke – early triage and inpatient rehabilitation may reduce long term costs. Swiss Med Wkly. 2008;138(31-32):459–65.
  40. Husi B. Pflegefinanzierung (Festlegung des kantonalen Vergütungs anteils 2012 im Bereich der Akut- und Übergangspflege). Auszug aus dem Protokoll des Regierungsrates des Kantons Zürich 2011; Sitzung vom 23. März 2011.
  41. Landesindex der Konsumentenpreise. Neuchâtel: Swiss Federal Office of Statistics; 2011 [updated 2011; cited 2011 September 30]. Available from:
  42. Brønnum-Hansen H, Davidsen M, Thorvaldsen P, Group ftDMS. Long-term survival and causes of death after stroke. Stroke. 2001;32(9):2131–6.
  43. Minn YK, Cho SJ, Kim SG, Kwon KH, Kim JH, Oh MS, et al. Long-term outcomes of acute ischemic stroke in patients aged 80 years and older. Yonsei Med J. 2008;49(3):400–4.
  44. Sullivan PW, Arant TW, Ellis SL, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. PharmacoEconomics. 2006;24(10):1021–33.
  45. Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. PharmacoEconomics. 2003;21(3):191–200.
  46. Hentrich DP, Fritschi J, Muller PR, Wuillemin WA. INR comparison between the CoaguCheck S and a standard laboratory method among patients with self-management of oral anticoagulation. Thromb Res. 2007;119(4):489–95.
  47. Wieloch M, Själander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J. 2011;32(18):2282–9.
  48. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a “real world” atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107(3):584–9.
  49. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics. 2008;26(9):733–44.
  50. World economic outlook database. International Monetary Fund; 2011 [updated 2011; cited 2011 September 30]. Available from:
  51. WHO cost-effectiveness thresholds. World Health Organization; 2012 [updated 2011; cited 2012 January 22]. Available from:
  52. Federal Supreme Court of Switzerland. Judgement of 23 November 2010. 9C 334/2010 2011.

Most read articles by the same author(s)